 |
|
|
| |
Ledipasvir/Sofosbuvir Fixed-Dose Combination
Is Safe and Effective in Difficult-to-Treat Populations Including GT 3 Patients, Decompensated GT 1 Patients,
and GT 1 Patients With Prior Sofosbuvir Experience
|
| |
| |
Reported by Jules Levin
EASL 2013 April 9-13 London, UK
Edward J. Gane,1 Robert H. Hyland,2 Di An,2 Phillip S. Pang,2 William T.
Symonds,2 John G. McHutchison,2 Catherine A. Stedman3
1Auckland Clinical Studies Ltd, Auckland, New Zealand; 2Gilead Sciences, Inc., Foster City, CA, USA; 3Christchurch Clinical Studies Trust, Christchurch, New Zealand
|
| |
|
|
|
|
|
